c-MET (Y1230A)

MET · Variant type: point · HGVS: p.Y1230A

Drug response on this variant

#	Drug	Inhibition on variant	Residual	KISS
1	Cabozantinib	97.9%	2.1%	92.73
2	Crizotinib	91.7%	8.3%	91.39
3	Gilteritinib	89.4%	10.6%	88.97
4	Tivozanib	82.5%	17.5%	92.42
5	Pacritinib	64.8%	35.2%	88.64
6	Lenvatinib	55.2%	44.8%	97.74
7	Defactinib	54.1%	45.9%	92.68
8	Repotrectinib	52.1%	47.9%	84.21
9	Afatinib	44.4%	55.6%	98.50
10	Fostamatinib	44.2%	55.8%	96.74
11	Vemurafenib	41.8%	58.2%	96.49
12	Selpercatinib	40.8%	59.2%	96.72
13	Axitinib	38.7%	61.3%	93.23
14	Neratinib	38.6%	61.4%	93.18
15	Fedratinib	38.2%	61.8%	96.21
16	Sunitinib	29.9%	70.1%	91.73
17	Dacomitinib	26.7%	73.3%	97.99
18	Canertinib	25.2%	74.8%	96.49
19	Brigatinib	24.7%	75.3%	82.96
20	Entrectinib	23.3%	76.7%	93.69
21	Ponatinib	21.7%	78.3%	78.23
22	Dabrafenib	21.1%	78.9%	94.74
23	Gefitinib	19.7%	80.3%	99.25
24	Bosutinib	18.0%	82.0%	87.22
25	Nintedanib	17.8%	82.2%	90.23

Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).

Drug	Variant inh	WT inh	Δ (variant − WT)
Cabozantinib	97.9%	—	—
Crizotinib	91.7%	—	—
Gilteritinib	89.4%	—	—
Tivozanib	82.5%	—	—
Pacritinib	64.8%	—	—
Lenvatinib	55.2%	—	—
Defactinib	54.1%	—	—
Repotrectinib	52.1%	—	—
Afatinib	44.4%	—	—
Fostamatinib	44.2%	—	—
Vemurafenib	41.8%	—	—
Selpercatinib	40.8%	—	—
Axitinib	38.7%	—	—
Neratinib	38.6%	—	—
Fedratinib	38.2%	—	—
Sunitinib	29.9%	—	—
Dacomitinib	26.7%	—	—
Canertinib	25.2%	—	—
Brigatinib	24.7%	—	—
Entrectinib	23.3%	—	—
Ponatinib	21.7%	—	—
Dabrafenib	21.1%	—	—
Gefitinib	19.7%	—	—
Bosutinib	18.0%	—	—
Nintedanib	17.8%	—	—

Loading…

Served from saifudeen2026@1.0.0 · API 0.1.0 · 41.1ms